Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
Recruiting · NCT06215651 · Registry updated 2024-04-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma | Cadonilimab and Lenvatinib | Recruiting | Phase 2 | 2024-04-01 | NCT06215651 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking Union Medical College Hospital | 417 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hai-Tao Zhao | Beijing | China | 1 |